Last reviewed · How we verify
Combigan Two Times Daily (BID)
Combigan combines a beta-adrenergic antagonist and an alpha-2 adrenergic agonist to reduce intraocular pressure by decreasing aqueous humor production and increasing uveoscleral outflow.
Combigan combines a beta-adrenergic antagonist and an alpha-2 adrenergic agonist to reduce intraocular pressure by decreasing aqueous humor production and increasing uveoscleral outflow. Used for Open-angle glaucoma, Ocular hypertension.
At a glance
| Generic name | Combigan Two Times Daily (BID) |
|---|---|
| Sponsor | Cornerstone Health Care, PA |
| Drug class | Fixed-dose combination of alpha-2 adrenergic agonist and beta-blocker |
| Target | Alpha-2 adrenergic receptor; beta-1 and beta-2 adrenergic receptors |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | FDA-approved |
Mechanism of action
Brimonidine tartrate (alpha-2 agonist) stimulates alpha-2 adrenergic receptors to reduce aqueous humor production and enhance uveoscleral outflow. Timolol maleate (non-selective beta-blocker) decreases aqueous humor secretion by inhibiting beta-adrenergic receptors on the ciliary body. The combination provides additive IOP-lowering effects.
Approved indications
- Open-angle glaucoma
- Ocular hypertension
Common side effects
- Ocular hyperemia
- Eye irritation/discomfort
- Blurred vision
- Allergic conjunctivitis
- Dry eye
- Headache
- Fatigue
Key clinical trials
- Comparison of Efficacy and Ocular Surface Assessment Between BRIDIN-plus and Combigan in Glaucoma or Ocular Hypertensive (PHASE4)
- BREMEN Eye Drops Versus Combigan for Open-angle Glaucoma or Intraocular Hypertension (PHASE3)
- Prophylaxis for Anti-VEGF-induced IOP Elevation (NA)
- Effect of Lowering IOP in Glaucoma Suspects With HM (NA)
- 24-Hour Intraocular Pressure With Brinzolamide/Timolol Versus Brimonidine/Timolol (PHASE4)
- Comparison of Combigan Two Times Daily (BID) Versus Simbrinza Three Times Daily (TID) (PHASE4)
- Efficacy and Safety of COMBIGAN® in Korean Patients With Primary Open Angle Glaucoma (POAG) and Normal Tension Glaucoma (NTG) (PHASE4)
- The Relationship Between Intraocular Pressure and Macular Edema in Patients With Diabetic Macular Edema (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Combigan Two Times Daily (BID) CI brief — competitive landscape report
- Combigan Two Times Daily (BID) updates RSS · CI watch RSS
- Cornerstone Health Care, PA portfolio CI